文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1 B亚型gp120多态性与fostemsavir耐药潜在关联的鉴定

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

研究分析了Los Alamos HIV数据库中1997条HIV-1 B亚型gp120序列,评估fostemsavir天然耐药突变频率及其与gp120多态性的关联。结果显示已知耐药突变频率较低,但部分耐药位点与特定gp120多态性显著相关,且聚集于I/II类限制性T细胞/抗体表位,提示潜在免疫逃逸作用,需进一步体外研究。

要点

  • HIV-1 B亚型中fostemsavir已知耐药突变频率低,但存在与耐药位点相关的gp120多态性。
  • S375M和S375T在X4病毒中频率显著高于R5病毒。
  • 多个耐药位点与特定gp120多态性正相关,且聚集于免疫表位区域。

核心结论

  • HIV-1 B亚型中已知fostemsavir耐药突变频率较低,但检测到可能与耐药相关的新gp120多态性,需进一步体外研究验证。

研究设计与样本

  • 基于Los Alamos HIV数据库的1997条HIV-1 B亚型gp120序列进行突变频率和关联分析,并评估蛋白稳定性及免疫表位结合影响。

主要发现

  • fostemsavir耐药突变频率:L116Q 0.05%,S375H/M/T 0.55%/1.35%/17.73%,M426L 7.56%,M434I 4.21%,M475I 1.65%;M426R多态性频率16.32%。
  • X4病毒中S375M频率显著高于R5病毒(0.69% vs 3.93%,P=0.009),S375T亦显著(16.60% vs 22.11%,P=0.030)。
  • S375T与I371V、S375M与L134W/I154V/I323T、M475I与K322A、M426R与G167N/K192T/S195N呈正相关,且聚类于I/II类限制性T细胞/抗体表位。

临床怎么用

  • 临床检测fostemsavir耐药时,除已知耐药位点外,需关注与耐药位点连锁的gp120多态性及其免疫逃逸潜力。

局限性

  • 基于数据库序列的回顾性分析,未进行体外表型验证,且部分突变(如S375T)对耐药的实际贡献有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated natural resistance to the new antiretroviral fostemsavir and its potential association with other HIV-1 gp120 polymorphisms. METHODS: A total of 1997 HIV-1 B subtype gp120 sequences from the Los Alamos HIV Database were analysed for mutation prevalence at fostemsavir resistance-associated positions and potential association with other gp120 polymorphisms. The role of each fostemsavir resistance-related position and the correlated gp120 mutations, both in protein stability and in reducing the binding affinity between antibody and/or T cell lymphocyte epitopes and the MHC molecules, was estimated. RESULTS: The prevalence of fostemsavir resistance mutations was as follows: L116Q (0.05%), S375H/M/T (0.55%/1.35%/17.73%, the latter being far less relevant in determining resistance), M426L (7.56%), M434I (4.21%) and M475I (1.65%). Additionally, the M426R polymorphism had a prevalence of 16.32%. A significantly higher prevalence in X4 viruses versus R5 viruses was found only for S375M (0.69% versus 3.93%, P = 0.009) and S375T (16.60% versus 22.11%, P = 0.030). Some fostemsavirv resistance positions positively and significantly correlated with specific gp120 polymorphisms: S375T with I371V; S375M with L134W, I154V and I323T; M475I with K322A; and M426R with G167N, K192T and S195N. The topology of the dendrogram suggested the existence of three distinct clusters (bootstrap ≥0.98) involving these fostemsavir resistance mutations and gp120 polymorphisms. Interestingly, all clustered mutations are localized in class I/II-restricted T cell/antibody epitopes, suggesting a potential role in immune HIV escape. CONCLUSIONS: A low prevalence of known fostemsavir resistance mutations was found in the HIV-1 B subtype. The detection of novel HIV-1 gp120 polymorphisms potentially relevant for fostemsavir resistance deserves new in-depth in vitro investigations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bouba Y, Berno G, Fabeni L, et al. Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. J Antimicrob Chemother. 2020. PMID: 32160290. doi:10.1093/jac/dkaa073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。